A New Category: Continuous Hormone Monitoring on the Wrist
Clair Health’s hormone tracking wearable is a jewelry-style, wrist‑worn noninvasive wearable device designed to infer key reproductive hormone patterns continuously, giving women cycle‑level, day‑to‑day hormone insights without relying on blood draws, urine strips, or other invasive testing methods that provide only occasional snapshots. The startup has raised USD 11.6 million (approx. RM54 million) in seed funding led by Khosla Ventures, with participation from a16z speedrun and other investors, to bring this continuous hormone monitoring platform to market. Clair’s device focuses on estrogen, progesterone, luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), modeling their activity from physiological signals such as skin temperature, heart rate variability and electrodermal activity. Rather than a traditional medical gadget, the product is framed as jewelry‑inspired women’s health technology, launching as a wellness wearable with plans to seek regulatory clearance later. If successful, it could expand hormone data from occasional lab tests to a continuous, longitudinal endocrine data layer.
Inside the Tech: AI, Biosensors and a Noninvasive Endocrine Data Layer
Clair’s hormone tracking wearable relies on a stack of 10 biosensors, including biomagnetic sensors, to collect multiple streams of physiological data that reflect hormonal effects throughout the body. Those raw signals feed AI models trained on more than 130 proprietary biomarkers, allowing the system to infer where a user is in her hormonal cycle rather than measuring hormone molecules directly. According to Pulse2, the company reports 94% accuracy in classifying menstrual cycle phases when benchmarked against daily urine samples, and an independent study through the Stanford Gladstone BeeHive program is underway. The team is also experimenting with voice‑based biomarkers that could estimate cycle phase from a short conversation. By turning these signals into a continuous endocrine pattern, Clair is trying to build an “endocrine data layer” that can sit alongside existing metrics like sleep, heart rate variability and temperature trends inside consumer wearables.
Redefining Female Physiology: From Four Phases to Nine Sub‑Phases
One of the most striking claims from Clair’s beta testing is that its continuous hormone monitoring has revealed nine sub‑phases within the menstrual cycle, more than double the four phases most women learn about. If replicated in peer‑reviewed research, that finding suggests current textbook models of female physiology may be too coarse to reflect real‑world hormonal dynamics. Clair argues that many familiar wearable metrics—sleep quality, recovery, heart rate variability and even perceived exertion—are shaped by underlying endocrine shifts that go unseen in current devices. By mapping more granular phases, the noninvasive wearable device aims to improve timing for fertility and conception, illuminate conditions such as PCOS, and give clearer context around perimenopause. As co‑founder Jenny Duan notes, the physiological signals “have always been there; we just haven’t had something to read it until now,” pointing to a large gap between lived experience and available data.
From Snapshots to Trajectories: What Continuous Hormone Data Could Change
Clair’s approach mirrors past shifts in digital health, where continuous glucose monitors transformed how clinicians and users understand metabolic variability. In the same way, continuous hormone monitoring could move women’s health technology from single‑timepoint lab results to trend‑based insight: not just “What is my hormone level today?” but “How is my endocrine pattern changing over weeks or months, and does it matter?” Longevity.Technology notes that this shift is about trajectories rather than isolated readings, which is vital for using hormonal patterns as healthspan signals rather than viewing them only through a reproductive lens. For women tracking fertility, cycle‑linked mood, exercise performance or perimenopause symptoms, a hormone tracking wearable could offer more precise timing and earlier warning signs. The challenge now is turning these richer patterns into clear, actionable guidance for women, clinicians and researchers, rather than more data with no obvious next step.
Investor Confidence and the Future of Women’s Health Technology
The USD 11.6 million (approx. RM54 million) seed round signals rising investor confidence that noninvasive hormone‑centric wearables could define the next growth wave in women’s health technology. According to Athletech News, Clair’s waitlist already tops 25,000 people, and its first 5,000‑unit production run sold out six months before release, indicating strong early demand. The backing of Khosla Ventures, a16z speedrun and 23andMe co‑founder Anne Wojcicki reflects belief not only in a single device, but in the value of large‑scale, longitudinal hormonal datasets. a16z’s Emily Bennett says her firm wants women’s health to be “proactive, data‑driven, and deeply personalized,” framing Clair as infrastructure for that shift. With 57% of consumers already owning some form of wearable, the market is crowded on the wrist—but hormones remain a missing layer. If Clair can validate its claims in peer‑reviewed studies, its noninvasive wearable device could help define an emerging endocrine‑focused category.
